论文部分内容阅读
目的观察常规化疗药物联合表皮长因子受体(EGFR)靶向药物C225及人表皮生长因子受体-2(HER2)靶向药物trastuzumab对食管鳞状细胞癌细胞株HE-2增殖影响。方法常规化疗药物5-Fu分别与C225及trastuzumab联合应用于食管鳞状细胞癌细胞株HE-2,采用噻唑蓝法以及流式细胞仪检测不同处理组的抗肿瘤效果。结果 5-Fu联合C225作用24、48 h时,HE-2细胞增殖抑制率分别为(45.29±0.16)%、(70.63±0.10)%,明显高于5-Fu联合trastuzumab的细胞增殖抑制率(33.02±0.19)%、(50.08±0.20)%,差异有统计学意义(P<0.05);5-Fu联合C225作用24、48 h时,HE-2细胞凋亡率分别为(15.47±1.62)%、(26.89±1.12)%;明显高于5-Fu联合trastuzumab的细胞凋亡率(7.34±0.88)%、(15.56±0.97)%,差异有统计学意义(P<0.05)。结论 EGFR信号通路上的靶向治疗药物C225可以增加5-Fu抗食管鳞状细胞癌作用。
Objective To observe the effects of traditional chemotherapy combined with epidermal growth factor receptor (EGFR) targeting drug C225 and human epidermal growth factor receptor-2 (HER2) targeting trastuzumab on the proliferation of esophageal squamous cell carcinoma cell line HE-2. Methods Conventional chemotherapy drug 5-Fu was used in combination with C225 and trastuzumab respectively for esophageal squamous cell carcinoma cell line HE-2. The antitumor effects of different treatment groups were tested by MTT method and flow cytometry. Results The inhibitory rates of HE-2 cells proliferation were (45.29 ± 0.16)% and (70.63 ± 0.10)%, respectively, which were significantly higher than those of 5-Fu combined with C225 for 24 and 48 h 33.02 ± 0.19%, 50.08 ± 0.20% respectively), the difference was statistically significant (P <0.05). The apoptosis rates of HE-2 cells treated with 5-Fu and C225 for 24 and 48 h were (15.47 ± 1.62) % And (26.89 ± 1.12)% respectively, which was significantly higher than that of 5-Fu combined with trastuzumab (7.34 ± 0.88)% and (15.56 ± 0.97)%, respectively, with statistical significance (P <0.05). Conclusion The targeted therapeutic agent C225 on the EGFR signaling pathway can enhance 5-Fu anti-esophageal squamous cell carcinoma.